Table 4.

180-day heart failure event-risk by profile of symptoms and hemodynamics

Characteristic	HR (95%CI), p-value	HR† (95%CI), p-value	HR‡ (95%CI), p-value
Symptom and Hemodynamic Profile
Severe Symptoms*	3.38 (1.10–10.37), p=0.033 3.27 (1.07–10.08), p=0.039 3.19 (1.04–9.81), p=0.043
Poor Hemodynamics*	3.48 (1.26–9.66), p=0.016 3.85 (1.38–10.77), p=0.010 4.01 (1.43–11.22), p=0.008
Other Factors
Age	-	0.99 (0.98–1.02), p=0.987	-
Male	-	1.23 (0.73–2.06), p=0.442	-
College Education	-	0.64 (0.34–1.21), p=0.167	-
ACE/ARB	-	0.46 (0.26–0.83), p=0.009	0.47 (0.27–0.83), p=0.010
Aldosterone antagonist	-	1.03 (0.62–1.69), p=0.918	-
Cognitive dysfunction ¶	-	-	1.68 (1.02–2.75), p=0.040
Β-adrenergic blocker	-	-	0.55 (0.28–1.10), p=0.090

^*= relative to participants in the concordant profile.

^†= adjusted for among-group differences in age, gender, education, angiotensin converting enzyme inhibitor/angiotensin receptor blocker, and aldosterone antagonist.

^‡= retained factors from backward selection with removal of factors with a p-value >0.20. Factors entered into the model were age, gender, married/living with partner, race, body mass index, Charlson comorbidity index, education, mild cognitive dysfunction, heart failure duration, ischemic etiology, prescribed a β-adrenergic blocker, prescribed an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and prescribed an aldosterone antagonist.

^¶= assessed with the Montreal Cognitive Assessment

Abbreviations: CI = confidence interval, HR = hazards ratio, ACE/ARB= angiotensin converting enzyme inhibitor/ angiotensin receptor blocker